Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02544308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Study acronym: IDRIS
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 23, 2022 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Primary completion date: Oct 2022 to Apr 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 140 to confirmed 36
    • Site details revised at 13 of 13 sites
    v6
  3. Primary completion date: Oct 2021 to Oct 2022
    • Study completion date: Dec 2025 to Dec 2026
    v5
  4. Study sites: 2 to 13v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 2016 to Mar 10, 2017
    • Study sites: 0 to 2
    • Eligibility criteria shortened, about 33 words
    v3
  6. Primary completion date: Dec 2022 to Oct 2021
    • Start date: Dec 2015 to Dec 2016
    • Eligibility criteria expanded, about 163 words
    • Collaborators revised (2)
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the trial is to establish whether adjuvant therapy with lenalidomide + dexamethasone after radiotherapy can improve progression free survival in patients with high risk solitary bone plasmacytoma compared with RT only.
Trial Details
NCT Number NCT02544308
Lead Sponsor University College, London
Collaborators: Cancer Research UK, Celgene
Conditions
(from sponsor)		 Plasmacytoma
Related terms Plasmacytoma
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov